DK0463101T3 - Vaccination og fremgangsmåde mod sygdomme, som skyldes patogene reaktioner og specifikke T-cellepopulationer - Google Patents

Vaccination og fremgangsmåde mod sygdomme, som skyldes patogene reaktioner og specifikke T-cellepopulationer

Info

Publication number
DK0463101T3
DK0463101T3 DK90905821.6T DK90905821T DK0463101T3 DK 0463101 T3 DK0463101 T3 DK 0463101T3 DK 90905821 T DK90905821 T DK 90905821T DK 0463101 T3 DK0463101 T3 DK 0463101T3
Authority
DK
Denmark
Prior art keywords
vaccination
treatment
specific
cell populations
diseases caused
Prior art date
Application number
DK90905821.6T
Other languages
Danish (da)
English (en)
Inventor
Mark D Howell
Steven W Brostoff
Dennis J Carlo
Original Assignee
Immune Response Corp Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27406453&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0463101(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immune Response Corp Inc filed Critical Immune Response Corp Inc
Application granted granted Critical
Publication of DK0463101T3 publication Critical patent/DK0463101T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK90905821.6T 1989-03-21 1990-03-21 Vaccination og fremgangsmåde mod sygdomme, som skyldes patogene reaktioner og specifikke T-cellepopulationer DK0463101T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32631489A 1989-03-21 1989-03-21
US38208589A 1989-07-18 1989-07-18
US38208689A 1989-07-18 1989-07-18

Publications (1)

Publication Number Publication Date
DK0463101T3 true DK0463101T3 (da) 1994-03-14

Family

ID=27406453

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90905821.6T DK0463101T3 (da) 1989-03-21 1990-03-21 Vaccination og fremgangsmåde mod sygdomme, som skyldes patogene reaktioner og specifikke T-cellepopulationer

Country Status (14)

Country Link
EP (1) EP0463101B2 (ko)
JP (1) JP3472297B2 (ko)
KR (1) KR920700674A (ko)
AU (5) AU672313B2 (ko)
BG (1) BG61164B1 (ko)
CA (1) CA2046909A1 (ko)
DE (1) DE69006018T3 (ko)
DK (1) DK0463101T3 (ko)
ES (1) ES2062519T5 (ko)
FI (1) FI914432A0 (ko)
NO (2) NO309164B1 (ko)
RO (1) RO110397B1 (ko)
RU (1) RU2138512C1 (ko)
WO (1) WO1990011294A1 (ko)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612035A (en) * 1989-03-21 1997-03-18 The Immune Response Corporation Vaccination against diseases resulting from pathogenic responses by specific T cell populations
US6221352B1 (en) 1989-03-21 2001-04-24 The Immune Response Corporation Method of preventing the proliferation of Vβ14 or Vβ17-Expressing T cells
US6207645B1 (en) 1989-03-21 2001-03-27 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations
US5776459A (en) * 1989-07-19 1998-07-07 Connetics Corporation TCR V beta 5 peptides
US5298396A (en) * 1989-11-15 1994-03-29 National Jewish Center For Immunology And Respiratory Medicine Method for identifying T cells disease involved in autoimmune disease
JPH06507384A (ja) * 1991-01-22 1994-08-25 ザ　イミューン　レスポンス　コーポレイション 特定のｔ細胞群による病理的応答により生じる疾患に対するワクチン投与および方法
EP0587735B1 (en) * 1991-05-31 2000-01-26 Connetics Corporation T cell receptor peptides as therapeutics for immune-related disease
WO1993004695A1 (en) * 1991-08-28 1993-03-18 The Wistar Institute T cell receptor-based therapy for rheumatoid arthritis
WO1993006135A1 (en) * 1991-09-23 1993-04-01 Genentech, Inc. Diagnosing and treating autoimmune disorders
WO1993012814A2 (en) * 1991-12-24 1993-07-08 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations
AU4529793A (en) * 1992-06-08 1994-01-04 Colorado State University Research Foundation Endogenous ligands for cdr4 of t-cell receptor beta -chains and genes encoding the same
AU6376194A (en) * 1993-05-14 1994-12-12 Dr. L. Willems-Instituut Human t cell monoclone, process for its production and its use, diagnostic of infectious diseases, autoimmune diseases, t-cell mediated allergies and cancer
US5552300A (en) * 1994-01-13 1996-09-03 T Cell Sciences, Inc. T cell antigen receptor V region proteins and methods of preparation thereof
US6034064A (en) * 1995-04-07 2000-03-07 Hoechst Pharmaceuticals & Chemicals K.K. Peptides and therapeutic agent for autoimmune diseases containing the same
JP2004512262A (ja) 2000-06-20 2004-04-22 アイデック　ファーマスーティカルズ　コーポレイション 非放射性抗ｃｄ２０抗体／放射標識抗ｃｄ２２抗体の組合せ
US20020159996A1 (en) 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
EP1370292A1 (en) 2001-01-31 2003-12-17 Idec Pharmaceuticals Corporation Use of cd23 antagonists for the treatment of neoplastic disorders
EP3263596A1 (en) 2002-12-16 2018-01-03 Genentech, Inc. Immunoglobulin variants and uses thereof
CA2519870A1 (en) 2003-04-09 2004-10-28 Genentech, Inc. Use of rituximab intravenous compositions to treat rheumatoid arthritis
CN106075435A (zh) 2004-06-04 2016-11-09 健泰科生物技术公司 用于治疗多发性硬化的方法
EP2548575A1 (en) 2005-02-15 2013-01-23 Duke University Anti-CD19 antibodies that mediate ADCC for use in treating autoimmune diseases
KR20070110077A (ko) 2005-03-10 2007-11-15 제넨테크, 인크. 혈관 완전성을 조정하기 위한 방법 및 조성물
CA2607281C (en) 2005-05-05 2023-10-03 Duke University Anti-cd19 antibody therapy for autoimmune disease
EP1999148B8 (en) 2006-03-06 2014-03-05 Medlmmune, LLC Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
KR20100017514A (ko) 2007-05-07 2010-02-16 메디뮨 엘엘씨 항 ｉｃｏｓ 항체, 및 종양, 이식 및 자가면역성 질환 치료에서의 이의 용도
WO2009038684A1 (en) 2007-09-14 2009-03-26 Biogen Idec Ma Inc. Compositions and methods for the treatment of progressive multifocal leukoencephalopathy (pml)
WO2009070642A1 (en) 2007-11-28 2009-06-04 Medimmune, Llc Protein formulation
EP2113560A1 (en) * 2008-04-28 2009-11-04 TXCell Compositions for treating an arthritic condition
CA2723614C (en) 2008-05-16 2015-07-14 Genentech, Inc. Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
AU2009303304A1 (en) 2008-10-10 2010-04-15 Anaphore, Inc. Polypeptides that bind TRAIL-RI and TRAIL-R2
EP2358392B1 (en) 2008-11-12 2019-01-09 MedImmune, LLC Antibody formulation
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
CN102369215B (zh) 2009-04-02 2015-01-21 罗切格利卡特公司 包含全长抗体和单链Fab片段的多特异性抗体
ES2513292T3 (es) 2009-07-31 2014-10-24 Genentech, Inc. Inhibición de metástasis tumoral usando anticuerpos anti-G-CSF
BR112012005893A2 (pt) 2009-09-16 2016-11-22 Genentech Inc hélice enrolada e/ou complexos de proteínas contendo conectores e usos dos mesmos
CA2772670A1 (en) 2009-09-17 2011-03-24 F. Hoffmann-La Roche Ag Methods and compositions for diagnostics use in cancer patients
WO2011060015A1 (en) 2009-11-11 2011-05-19 Genentech, Inc. Methods and compositions for detecting target proteins
CA2781682A1 (en) 2009-12-04 2011-06-09 Genentech, Inc. Multispecific antibodies, antibody analogs, compositions, and methods
AR080793A1 (es) 2010-03-26 2012-05-09 Roche Glycart Ag Anticuerpos biespecificos
CA2796633C (en) 2010-04-23 2020-10-27 Genentech, Inc. Production of heteromultimeric proteins
CA2807278A1 (en) 2010-08-24 2012-03-01 F. Hoffmann - La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
KR20210021109A (ko) 2010-11-08 2021-02-24 제넨테크, 인크. 피하 투여용 항―ｉｌ―6 수용체 항체
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
BR112013019499B1 (pt) 2011-02-04 2023-01-10 Genentech, Inc. Proteína heteromultimérica variante ou anticorpo igg modificado, método para produzir uma proteína heteromultimérica variante ou anticorpo igg modificado, composição, método para preparar uma proteína heteromultimérica e proteína heteromultimérica variante
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
RU2016127812A (ru) 2011-03-31 2018-12-06 Дженентек, Инк. Способы введения антагонистов интегрина бета7
WO2013013708A1 (en) 2011-07-26 2013-01-31 Fundació Institut D'investigació Biomèdica De Bellvitge Treatment of acute rejection in renal transplant
EP2744825A1 (en) 2011-08-17 2014-06-25 F.Hoffmann-La Roche Ag Inhibition of angiogenesis in refractory tumors
WO2013082511A1 (en) 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
US20130243750A1 (en) 2012-01-31 2013-09-19 Genentech, Inc. Anti-ige antibodies and methods using same
EP2812357B1 (en) 2012-02-10 2020-11-04 F.Hoffmann-La Roche Ag Single-chain antibodies and other heteromultimers
NZ628126A (en) 2012-02-16 2016-10-28 Atyr Pharma Inc Histidyl-trna synthetases for treating autoimmune and inflammatory diseases
CN104411718B (zh) 2012-06-27 2018-04-24 弗·哈夫曼-拉罗切有限公司 用于制备包含特异性结合靶的至少一种结合实体的抗体Fc区缀合物的方法及其用途
CN104395339A (zh) 2012-06-27 2015-03-04 弗·哈夫曼-拉罗切有限公司 用于选择并产生含有至少两种不同结合实体的定制高度选择性和多特异性靶向实体的方法及其用途
ES2738305T3 (es) 2012-10-05 2020-01-21 Hoffmann La Roche Procedimientos para diagnosticar y tratar enfermedades inflamatorias intestinales
CN105247072B (zh) 2013-02-25 2019-10-15 基因泰克公司 检测和治疗抗药性akt突变体的方法和组合物
WO2014151517A1 (en) 2013-03-15 2014-09-25 Intermune, Inc. Methods of improving microvascular integrity
KR102175688B1 (ko) 2013-03-27 2020-11-06 제넨테크, 인크. 베타7 인테그린 길항제를 사용하는 위장 염증성 장애의 치료를 평가하기 위한 바이오마커의 사용
KR20220065091A (ko) 2014-03-27 2022-05-19 제넨테크, 인크. 염증성 장 질환의 진단 및 치료 방법
WO2015171822A1 (en) 2014-05-06 2015-11-12 Genentech, Inc. Production of heteromultimeric proteins using mammalian cells
MX2017003022A (es) 2014-09-12 2017-05-12 Genentech Inc Anticuerpos anti-cll-1 e inmunoconjugados.
EP3227332B1 (en) 2014-12-03 2019-11-06 F.Hoffmann-La Roche Ag Multispecific antibodies
HUE045216T2 (hu) 2014-12-05 2019-12-30 Hoffmann La Roche Anti-CD79B antitestek és alkalmazási eljárások
WO2016138207A1 (en) 2015-02-26 2016-09-01 Genentech, Inc. Integrin beta7 antagonists and methods of treating crohn's disease
WO2016205200A1 (en) 2015-06-16 2016-12-22 Genentech, Inc. Anti-cll-1 antibodies and methods of use
BR112017024610A2 (pt) 2015-06-24 2018-07-31 F. Hoffmann-La Roche Ag anticorpos para receptor antitransferrina com afinidade especificada
AU2016285596A1 (en) 2015-06-29 2018-01-18 Genentech, Inc. Type II anti-CD20 antibody for use in organ transplantation
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
CN114031689A (zh) 2015-10-02 2022-02-11 豪夫迈·罗氏有限公司 双特异性抗人cd20/人转铁蛋白受体抗体及使用方法
JP2018529747A (ja) 2015-10-06 2018-10-11 ジェネンテック， インコーポレイテッド 多発性硬化症を治療するための方法
BR112018010945A2 (pt) 2015-12-30 2018-12-04 Genentech Inc formulações com degradação de polissorbato reduzida
WO2017201449A1 (en) 2016-05-20 2017-11-23 Genentech, Inc. Protac antibody conjugates and methods of use
CA3044526A1 (en) 2016-12-07 2018-06-14 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
WO2018112235A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a smad7 inhibitor
WO2018112237A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor
CA3045310A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
AU2017378406A1 (en) 2016-12-14 2019-06-13 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immunosuppressant
CA3046019A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a tlr modulator
MX2019006821A (es) 2016-12-14 2019-10-21 Progenity Inc Tratamiento de una enfermedad del tracto gastrointestinal con un inhibidor de cinasa de janus (jak) y dispositivos.
CA3045307A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
BR112019011702A2 (pt) 2016-12-14 2019-10-22 Progenity Inc tratamento de uma doença do trato gastrointestinal com um inibidor de il-12/il-23 liberado usando um dispositivo ingerível
WO2018183931A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with il-10 or an il-10 agonist
JP2020515579A (ja) 2017-03-30 2020-05-28 プロジェニティ， インコーポレイテッド 消化管疾病の生菌生物学的製剤による治療
WO2018183932A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
WO2018183934A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a chst15 inhibitor
EP3672586A1 (en) 2017-08-23 2020-07-01 Kezar Life Sciences Immunoproteasome inhibitors and immunosuppressive agent in the treatment of autoimmune disorders
RU2698048C2 (ru) 2017-10-03 2019-08-21 Закрытое Акционерное Общество "Биокад" МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
WO2019147824A1 (en) 2018-01-26 2019-08-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
CN112400024B (zh) 2018-06-01 2024-04-09 比奥拉治疗股份有限公司 用于胃肠道微生物组检测和处理的装置和系统
US20230009902A1 (en) 2018-06-20 2023-01-12 Progenity, Inc. Treatment of a disease or condition in a tissue orginating from the endoderm
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
EP3870235A1 (en) 2018-10-24 2021-09-01 F. Hoffmann-La Roche AG Conjugated chemical inducers of degradation and methods of use
RU2724469C2 (ru) 2018-10-31 2020-06-23 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с cd20
EP3883636A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
WO2020104705A2 (en) 2018-11-23 2020-05-28 Katholieke Universiteit Leuven Predicting a treatment response in inflammatory bowel disease
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
CN112805026A (zh) 2019-02-06 2021-05-14 桑格摩生物治疗股份有限公司 用于治疗i型黏多糖贮积症的方法
BR112021019448A2 (pt) 2019-04-02 2021-11-30 Sangamo Therapeutics Inc Métodos para o tratamento de beta-talassemia
EP4309722A2 (en) 2019-12-13 2024-01-24 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
WO2023086910A1 (en) 2021-11-12 2023-05-19 Genentech, Inc. Methods of treating crohn's disease using integrin beta7 antagonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4886743A (en) * 1985-04-24 1989-12-12 California Institute Of Technology Diagnostic reagents based on unique sequences within the variable region of the T cell receptor and uses thereof
KR960001741B1 (ko) * 1985-12-03 1996-02-05 티 셀 사이언시즈, 인코포레이티드 세포-없는 t 세포항원 수용체 단백질의 감지방법
FI891226A (fi) * 1988-04-28 1989-10-29 Univ Leland Stanford Junior Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom.

Also Published As

Publication number Publication date
NO20002425L (no) 1991-09-20
JPH04506512A (ja) 1992-11-12
KR920700674A (ko) 1992-08-10
DE69006018T2 (de) 1994-05-11
NO913722D0 (no) 1991-09-20
AU672313B2 (en) 1996-09-26
CA2046909A1 (en) 1990-09-22
DE69006018D1 (de) 1994-02-24
WO1990011294A1 (en) 1990-10-04
EP0463101B2 (en) 2003-03-19
JP3472297B2 (ja) 2003-12-02
NO913722L (no) 1991-09-20
ES2062519T5 (es) 2003-07-16
DE69006018T3 (de) 2004-01-15
ES2062519T3 (es) 1994-12-16
RU2138512C1 (ru) 1999-09-27
BG61164B1 (bg) 1997-01-31
EP0463101B1 (en) 1994-01-12
AU6892694A (en) 1994-10-27
EP0463101A1 (en) 1992-01-02
RO110397B1 (ro) 1996-01-30
FI914432A0 (fi) 1991-09-20
NO309164B1 (no) 2000-12-18
AU5356790A (en) 1990-10-22
AU648753B2 (en) 1994-05-05
AU6892994A (en) 1994-10-27
AU6893094A (en) 1994-11-24
AU7650096A (en) 1997-02-13
AU6892894A (en) 1994-11-03
NO20002425D0 (no) 2000-05-10

Similar Documents

Publication Publication Date Title
DK0463101T3 (da) Vaccination og fremgangsmåde mod sygdomme, som skyldes patogene reaktioner og specifikke T-cellepopulationer
FR2593809B1 (fr) Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique
DK658688D0 (da) 1-aryl-3-quinolin- og 1-aryl-3-isoquinolin-carboxamider, deres fremstilling og anvendelse som laegemidler
NO900227L (no) Ekstruderbar elastisk gel for anvendelse som baerer for terapeutisk middel.
DK143588D0 (da) Substituerede 9-amino-tetrahydroacridiner, deres fremstilling og anvendelse som laegemidler
DK0386793T3 (da) 1alfa-hydroxyvitamin D2 epimer og derivater heraf
FI872756A (fi) Med laserstraolning fungerande terapeutisk anordning.
DK209188A (da) Bifunktionelle proteiner, deres fremstilling og anvendelse som laegemiddel
NO884022D0 (no) Steriliseringspakning for engangsbruk.
DK170487D0 (da) Farveloese ketiminer, fremstilling og anvendelse deraf som tvaerbindingsmiddel
DK55088A (da) 3,4-dihydro-2h-benzo(b)pyraner, deres fremstilling og anvendelse som laegemidler
DK131887A (da) 1,2,3,4-tetrahydro-3-carbamoyl-2-thioxo/oxo-5-pyrimidencarboxylsyre-derivater og deres anvendelse som laegemidler
DK366888D0 (da) Castanosperminestre og -glykosider, deres fremstilling og anvendelse som laegemidler
DE3687097T2 (de) Therapeutisches mittel zur behandlung haematopoietischer krankheiten.
FI894650A (fi) Antigen, som associerar till en human tumoer.
NO904576D0 (no) Aminopyridinylaminofenol og beslektede forbindelser, mellomprodukter, fremgangsmaate for deres fremstilling og anvendelse som medikamenter.
DK284688D0 (da) Beta-lactam-forbindelser, deres fremstilling og anvendelse som laegemidler
FI864995A0 (fi) Med solenergi driven straolningsanordning foer medicinskt bruk.
OA08730A (fr) Tampon en éponge élastique, notamment tampon vaginal.
DK501888D0 (da) 6-mercaptopurin-derivater, deres fremstilling og anvendelse som laegemidler
DE3761561D1 (de) N,n-bis-(4-fluorophenyl)carbamoylacetohydroxamsaeure und diese enthaltende pharmazeutische zusammensetzungen.
DK47788D0 (da) 14,15-substituerede lanosteroler og fysiologisk acceptable salte deraf og deres anvendelse som farmaceutika
KR870011251A (ko) 신규 항생물질 무레이도마이신 a, b, c 및 d 그의 제조 방법 및 치료학적 용도
NO885406D0 (no) Fremgangsmaate for fremstilling av 4-heteroaryl-1,3-benzodiazepiner og 2-substituerte-alfa-(hetero-aryl)benzenetanaminer og anvendelse derav som medikamenter.
DK182186D0 (da) Ethanobenzazepiner, fremgangsmaade og mellemprodukter til deres fremstilling og deres anvendelse som laegemidler